<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573975</url>
  </required_header>
  <id_info>
    <org_study_id>IRB097-76</org_study_id>
    <nct_id>NCT01573975</nct_id>
  </id_info>
  <brief_title>Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori</brief_title>
  <official_title>Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Buddhist Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the eradication efficacy of 10-day triple therapy
      with 10-day sequential therapy with tetracycline or metronidazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Antimicrobial resistance has decreased eradication rates for Helicobacter pylori
      infection worldwide.

      Objective: To determine whether sequential treatment eradicates H. pylori infection better
      than standard triple-drug therapy for adults with dyspepsia or peptic ulcers in Taiwanese
      people.

      Design: Randomized, single-blind, prospective controlled trial. Setting: A large tertiary
      referral hospital in eastern Taiwan. Patients: 450 patients with dyspepsia or peptic ulcers
      and infected by H. pylori.

      Measurements: 13C-urea breath test, upper endoscopy, histologic evaluation, rapid urease
      test, bacterial culture, assessment of antibiotic resistance and CYP2C19 genotype of host.

      Intervention: 450 patients with H. pylori infection are randomly assigned to receive one of
      the following therapeutic schemes: group A (5RA5RCT): rabeprazole (20 mg bid) plus
      amoxicillin (1 g bid) for 5 days, followed by rabeprazole (20 mg bid) plus clarithromycin
      (500 mg bid) and tetracycline (1g bid) for a further 5 days; group B (5RA5RCM): rabeprazole
      (20 mg bid) plus amoxicillin (1 g bid) for 5 days, followed by rabeprazole (20 mg bid) plus
      clarithromycin (500 mg bid) and metronidazole (500mg bid) for a further 5 days; group C as
      control: rabeprazole (20 mg bid) plus amoxicillin (1 g bid) and clarithromycin (500 mg bid.)
      for 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate</measure>
    <time_frame>4 weeks after complete use of drug for treatment</time_frame>
    <description>A negative post-treatment 13C-urea breath test or CLO test result at more than 4 weeks after complete use of drug for treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Seq-Metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-day sequential therapy with metronidazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seq-Tetracycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-day sequential therapy with tetracycline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10-day standard triple therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5RA-5RCM</intervention_name>
    <description>rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.</description>
    <arm_group_label>Seq-Metronidazole</arm_group_label>
    <other_name>Pariet x 10 days</other_name>
    <other_name>Hiconcil x 1st 5 days then</other_name>
    <other_name>Klaricid x last 5 days +</other_name>
    <other_name>Flagyl x last 5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5RA-5RCT</intervention_name>
    <description>rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.</description>
    <arm_group_label>Seq-Tetracycline</arm_group_label>
    <other_name>Pariet x 10 days</other_name>
    <other_name>Hiconcil x 1st 5 days then</other_name>
    <other_name>Klaricid x last 5 days +</other_name>
    <other_name>Acromycin x last 5 days.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10RCA</intervention_name>
    <description>rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Pariet x 10 days</other_name>
    <other_name>Klaricid x 10 days</other_name>
    <other_name>Hiconcil x 10 days.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient proved with infection of H. pylori in gastric mucosa

          -  adult with signed inform consent

        Exclusion Criteria:

          -  woman in breast feeding or pregnancy.

          -  allergy to drugs used in study.

          -  three months without use of any antibiotic agents.

          -  patients under 20 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Cheh CHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 Sep 1;24(5):845-50.</citation>
    <PMID>16918889</PMID>
  </reference>
  <reference>
    <citation>Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008 Jun 17;148(12):923-31. Epub 2008 May 19. Erratum in: Ann Intern Med. 2008 Sep 16;149(6):439.</citation>
    <PMID>18490667</PMID>
  </reference>
  <reference>
    <citation>Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007 Apr 17;146(8):556-63.</citation>
    <PMID>17438314</PMID>
  </reference>
  <reference>
    <citation>Choi WH, Park DI, Oh SJ, Baek YH, Hong CH, Hong EJ, Song MJ, Park SK, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. [Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea]. Korean J Gastroenterol. 2008 May;51(5):280-4. Korean.</citation>
    <PMID>18516011</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Buddhist Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Cheh Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>antibiotic resistance</keyword>
  <keyword>sequential therapy</keyword>
  <keyword>Taiwan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

